The global market for Duchenne Muscular Dystrophy Drugs is estimated at US$2.8 Billion in 2023 and is projected to reach US$27.4 Billion by 2030, growing at a CAGR of 33% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. ![Duchenne Muscular Dystrophy Drugs Market]( "Duchenne Muscular Dystrophy Drugs Market")
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Exon Skipping segment, which is expected to reach US$18.1 Billion by 2030 with a CAGR of 37.5%. The Steroid Therapy segment is also set to grow at 23.4% CAGR over the next 8 years.
- Regional Analysis: Gain insights into the U.S. market, estimated at $1.2 Billion in 2023, and China, forecasted to grow at an impressive 38.5% CAGR to reach $2.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Duchenne Muscular Dystrophy Drugs Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Duchenne Muscular Dystrophy Drugs Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Duchenne Muscular Dystrophy Drugs Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as FibroGen, Inc., ITALFARMACO S.p.A., NS Pharma Inc., and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 38 Featured):
- FibroGen, Inc.
- ITALFARMACO S.p.A.
- NS Pharma Inc.
- PTC Therapeutics, Inc.
- Sarepta Therapeutics, Inc.
- Satellos Bioscience, Inc.
MarketGlass Platform
Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
- A Prelude to Duchenne Muscular Dystrophy
- Global Economic Update
- Here’s How Inflationary Pressures Affect the Economy
- Here’s What’s Causing Inflationary Pressures in the Global Market
- World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020 Through 2024
- Impact of COVID-19 on Duchenne Muscular Dystrophy Drugs Market
- Competition
- Product Development as Hallmark of Global Duchenne Muscular Dystrophy Market
- Duchenne Muscular Dystrophy Drugs - Global Key Competitors Percentage Market Share in 2023 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
- Global Market Overview and Prospects
- Global Duchenne Muscular Dystrophy Drugs Market Set for a Rapid Growth, Driven by Rising Prevalence
- A Review of the Approved DMD Drugs
- North America and Europe to Remain Lucrative Markets
- Molecular Therapy, Hospital/Clinic & Hospital Pharmacy: Hale & Hearty Segments of Duchenne Muscular Dystrophy Market
- Dynamic Factors Keeping Duchenne Muscular Dystrophy Market Growing
- Market Drivers
- Rising Incidence of DMD to Catalyze Growth
- DMD Prevalence (in 100,000 Population) in Select Countries: 2020
- High Uptake of Novel Therapies & Drugs
- Market Restraints & Challenges
- Lack of Standardization for Clinical Efficacy
- Stringent Regulatory Regime
- Market Opportunities
- Product Developments & Rising Awareness
- Surge in Clinical Trials to Launch Novel Options
- Recent Market Activity
3. MARKET TRENDS & DRIVERS
- Rising R&D Investment to Boost DMD Market
- Select Therapy Candidates Under Development for Treating DMD
- Growing Government Support Propels Market Expansion
- Biologics - The Most Dynamic Segment of the Market
- Blossoming of Gene Therapy in Duchenne Muscular Dystrophy Treatment Domain
- Gene Therapy for DMD Treatment
- Elevidys, The First Ground-breaking Gene Therapy for Treatment of Duchenne Muscular Dystrophy (DMD)
- Children’s National Hospital Starts Offering Newly Approved Gene Therapy for DMD
- Promising Gene Therapies
- Potential Side-Effects & Risks of Gene Therapies
- Vamorolon Holds Potential to Lessen Health Risks Linked with Extended Use of Steriods
- DT-DEC01 Offers Promise to Stabilize or Improve Motor Function
- AOC 1044 Receives Orphan Drug Status for DMD44
- Italfarmaco Group Announces NDA Acceptance for Givinostat Targeting Duchenne Muscular Dystrophy
- Uptrend in Healthcare Expenditure Creates Substantial Opportunities
- World Healthcare Expenditure (In US$ Trillion) for the Years 2019, 2021 & 2023
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Duchenne Muscular Dystrophy Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2018 through 2030
- Table 2: World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 3: World Historic Review for Duchenne Muscular Dystrophy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 4: World 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2018, 2024 & 2030
- Table 5: World Recent Past, Current & Future Analysis for Exon Skipping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 6: World Historic Review for Exon Skipping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 7: World 12-Year Perspective for Exon Skipping by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
- Table 8: World Recent Past, Current & Future Analysis for Steroid Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 9: World Historic Review for Steroid Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 10: World 12-Year Perspective for Steroid Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
- Table 11: World Recent Past, Current & Future Analysis for Other Therapeutic Approaches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 12: World Historic Review for Other Therapeutic Approaches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 13: World 12-Year Perspective for Other Therapeutic Approaches by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
- Table 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 16: World 12-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Drug Store & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 18: World Historic Review for Drug Store & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 19: World 12-Year Perspective for Drug Store & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
- Table 20: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 21: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 22: World 12-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
UNITED STATES
- Table 23: USA Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 24: USA Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 25: USA 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030
- Table 26: USA Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 27: USA Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 28: USA 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030
CANADA
- Table 29: Canada Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 30: Canada Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 31: Canada 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030
- Table 32: Canada Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 33: Canada Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 34: Canada 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030
JAPAN
- Table 35: Japan Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 36: Japan Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 37: Japan 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030
- Table 38: Japan Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 39: Japan Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 40: Japan 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030
CHINA
- Table 41: China Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 42: China Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 43: China 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030
- Table 44: China Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 45: China Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 46: China 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030
EUROPE
- Table 47: Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 48: Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 49: Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2018, 2024 & 2030
- Table 50: Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 51: Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 52: Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030
- Table 53: Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 54: Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 55: Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030
FRANCE
- Table 56: France Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 57: France Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 58: France 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030
- Table 59: France Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 60: France Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 61: France 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030
GERMANY
- Table 62: Germany Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 63: Germany Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 64: Germany 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030
- Table 65: Germany Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 66: Germany Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 67: Germany 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030
ITALY
- Table 68: Italy Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 69: Italy Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 70: Italy 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030
- Table 71: Italy Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 72: Italy Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 73: Italy 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030
UNITED KINGDOM
- Table 74: UK Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 75: UK Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 76: UK 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030
- Table 77: UK Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 78: UK Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 79: UK 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030
REST OF EUROPE
- Table 80: Rest of Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 81: Rest of Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 82: Rest of Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030
- Table 83: Rest of Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 84: Rest of Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 85: Rest of Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030
ASIA-PACIFIC
- Table 86: Asia-Pacific Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 87: Asia-Pacific Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 88: Asia-Pacific 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030
- Table 89: Asia-Pacific Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 90: Asia-Pacific Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 91: Asia-Pacific 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030
REST OF WORLD
- Table 92: Rest of World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 93: Rest of World Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 94: Rest of World 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030
- Table 95: Rest of World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 96: Rest of World Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR
- Table 97: Rest of World 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- FibroGen, Inc.
- ITALFARMACO S.p.A.
- NS Pharma Inc.
- PTC Therapeutics, Inc.
- Sarepta Therapeutics, Inc.
- Satellos Bioscience, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 220 |
| Published | March 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 2.8 Billion |
| Forecasted Market Value ( USD | $ 27.4 Billion |
| Compound Annual Growth Rate | 33.0% |
| Regions Covered | Global |
